Drug profile · INN
aztreonam
CAYSTON
aztreonam (CAYSTON) is a bacterial penicillin-binding protein inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — aztreonam
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
aztreonam (CAYSTON) is a bacterial penicillin-binding protein inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is aztreonam?
aztreonam (CAYSTON) is a bacterial penicillin-binding protein inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for aztreonam?
CAYSTON is a marketed brand name for aztreonam. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aztreonam?
aztreonam has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.